[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100450419":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":33,"responsibleParty":53,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with newly diagnosed non-small cell lung cancer",null,"Approximately 1800 patients who are initiating\n\n* Standard of care, including targeted therapy based on PD-L1 status, EGFR, ALK or ROS1 (routine biomarkers)\n* Active clinical trials in the clinics after informed consent",[13],"Other: No Intervention: Observational Cohort",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients with metastatic breast cancer","Approximately 600 patients who are initiating\n\n* Standard of care, including targeted therapy based on HER2 status and ER status (routine biomarkers)\n* Active clinical trials in the clinics after informed consent",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"No Intervention: Observational Cohort","No intervention",[15,9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Ulrik Lassen, MD","CONTACT","+4535453545","ulrik.lassen@regionh.dk",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Andreas Bjerrum, MD","+4535450966","andreas.bjerrum@regionh.dk",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Rigshospitalet","RECRUITING","Copenhagen","2100","Denmark","DK",{"type":42,"coordinates":43},"Point",[44,45],12.56553,55.67594,{"lat":45,"lon":44},[48,49,50],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Ulrik Lassen, MD, PH.D","PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ulrik Lassen","Head of department","100450419","copenhagen-master-observational-trial-100450419",false,"NCT05145244","Copenhagen Master Observational Trial","Copenhagen Master Observational Trial (C-MOT): A Prospective Investigator-initiated Observational Study to Study Biomarkers in Relation to Clinical Outcome in Patients With Non-Small Cell Lung Cancer or Breast Cancer","C-MOT","Inclusion Criteria:\n\n* Patients (≥ 18 years of age) with diagnosis of NSCLC or breast cancer amenable to medical or radiation therapy with curative or palliative intent\n* Evidence of a personally signed and dated informed consent form document indicating that the patient has been informed of all pertinent aspects of the study\n* Able to read and understand Danish\n* Willing and able to complete collection of data including WGS\n\nExclusion Criteria:\n\n* Patient with breast cancer initiating adjuvant systemic therapy\n* In the judgment of the investigator, the patient's life expectancy is fewer than 3 months at the time of diagnosis of NSCLC or breast cancer","ALL","18 Years",{"count":67,"type":68},2400,"ESTIMATED","OBSERVATIONAL","The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC) or breast cancer receiving treatment offered in the clinic (standard of care or included in clinical trials).",[72,73],"Non-small Cell Lung Cancer","Breast Cancer",[75,76,77,78],"Real world data","Observational trial","WGS, whole genome sequencing","Patient Reported Outcomes, PRO","2026-08-11",{"date":81,"type":82},"2026-08-12","ACTUAL",{"date":84,"type":82},"2021-08-01",{"date":86,"type":68},"2027-12-31",{"name":5,"class":6},1]